Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- apixaban
- Kadcyla (ado-trastuzumab emtansine)
Interactions between your drugs
apixaban ado-trastuzumab emtansine
Applies to: apixaban, Kadcyla (ado-trastuzumab emtansine)
MONITOR CLOSELY: Coadministration of trastuzumab emtansine with anticoagulant or antiplatelet drugs may potentiate the risk of hemorrhagic events associated with these drugs. In clinical trials, fatal cases of hemorrhage occurred in patients receiving trastuzumab emtansine in addition to anticoagulant and antiplatelet therapy.
MANAGEMENT: Caution is recommended and additional monitoring should be considered if trastuzumab emtansine must be used with anticoagulant or antiplatelet drugs. In general, monitoring of platelet counts is recommended prior to each dose of trastuzumab emtansine. If platelet counts decrease to less than 50,000/mm3 (Grade 3 or higher), discontinue trastuzumab emtansine until platelet counts increase to 75,000/mm3 or higher (Grade 1 or less).
References (3)
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
- (2022) "Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Eliquis
Eliquis (apixaban) is used to reduce the risk of stroke and systemic embolism in patients with ...
Xarelto
Xarelto (rivaroxaban) is a factor Xa inhibitor used to reduce the risk of blood clots and stroke in ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Lovenox
Lovenox is used to prevent deep vein thrombosis (DVT) which can lead to blood clots in the lungs ...
Pradaxa
Pradaxa (dabigatran) is used to prevent stroke and blood clots in patients with atrial ...
Edoxaban
Edoxaban is used for atrial fibrillation, deep vein thrombosis, prevention of thromboembolism in ...
Fondaparinux
Fondaparinux is used for deep vein thrombosis, deep vein thrombosis prophylaxis after abdominal ...
Dabigatran
Dabigatran is used for deep vein thrombosis, deep vein thrombosis, prophylaxis, deep vein ...
Rivaroxaban
Rivaroxaban is used for atrial fibrillation, cardiovascular risk reduction, congenital heart ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.